The effect of KB003305, a liver selective glucocorticoid receptor antagonist, on fasting plasma glucose and oral glucose tolerance after multiple oral doses in patients with diabetes type 2
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2011
At a glance
- Drugs KB 3305 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 25 Jun 2010 Results presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA 2010).
- 31 Mar 2009 Resulst have been reported in a Karo Bio media release.
- 31 Mar 2009 Status changed from not yet recruiting to completed, as reported by Karo Bio in a media release.